Tamoxifen: Beyond the AntiestrogenSpringer Science & Business Media, 2012 M12 6 - 378 páginas Tamoxifen has persisted as a widely accepted and administered drug for almost 25 years. Following the many scientific papers and books on the subject, it has remained a very intriguing substance. This, perhaps, is the reason for another monograph on Tamoxifen. It is regrettably true that overviews, even when up to date after exhaustive research - the shibboleth of our cultures -, rapidly lose relevance with the passage of time. Scientists can sometimes be pictured as deep sea divers, who plunge into the unknown in search of a hitherto unknown world. Their descent is exciting, but eventually they must come up for air and integrate their experiences with others who also had to resurface. This book intends to collect and, where possible, to collate recent, but sometimes seemingly unrelated information. To quote Stephane Mallarme: "Everything in the world exists to end up in a book". Even if this is a tad cynical, it might not be far from the truth. If a little knowledge is a dangerous commodity, one can also add - tongue in cheek - that a vast amount of knowledge can be truly hazardous. It is likely that what might seem as entangled data is confusing, especially for those satisfied with the comfortable interpretation of Tamoxifen as an antiestrogen which has long been found insufficient. The complexity of its mechanisms and effects defies simple explanations and may even seem capricious, but only because of our ignorance. |
Contenido
Assessing Neoplasia | 25 |
Interactions of Tamoxifen with lipid signal transduction cascades | 42 |
Carcinogenicity of Tamoxifen | 68 |
Mechanisms of resistance to antiestrogens and their implications | 93 |
Tamoxifen and multidrug resistance in cancer | 123 |
The effect of Tamoxifen on the immune response | 137 |
Cellular effects of early exposure to Tamoxifen | 179 |
The covalent binding of Tamoxifen to proteins and | 201 |
Tamoxifen metabolism and receptor function implications for | 231 |
Tamoxifen and Ecadherincatenin complex | 267 |
Regulation of growth factor gene expression by Tamoxifen | 285 |
Tamoxifen and drugmetabolising enzymes | 302 |
Antiestrogen regulation of erbB2 expression in human breast | 343 |
Enhancement of the antineoplastic effects of Tamoxifen | 359 |
375 | |
Otras ediciones - Ver todas
Términos y frases comunes
4-hydroxytamoxifen activity of Tamoxifen agonist antiestrogens Baral Berczi binding of Tamoxifen Biochem Biol breast cancer cells breast cancer patients calmodulin cancer cell lines Cancer Res Carcinogenesis carcinogenicity catalyzed cellular Clin Oncol clinical concentrations covalent binding CYP3A cytotoxicity DNA adducts droloxifene drug E-cadherin effects of Tamoxifen endometrial cancer enhanced enzymes epithelial erbB2 estradiol estrogen receptor exposure expression function gene growth factor hepatic hormone human breast cancer IGF-I Iguchi increased induced inhibition inhibitors insulin-like growth insulin-like growth factor interaction invasion Jordan VC killer cells Kupfer levels lipid peroxidation Lippman liver microsomes lymphocytes malignant mammary MCF-7 cells mechanisms mediated membrane metabolism metabolites mice microsomes mRNA multidrug resistance Natl Cancer Inst neonatally neoplasms observed P-glycoprotein pathways Pharmacol potential proliferation protein kinase reactive intermediate regulation response serum somatostatin steroid stimulated studies Tamoxifen Tamoxifen resistance Tamoxifen therapy Tamoxifen treatment target cells tissue Toremifene transcription treated triphenylethylenes tumor uterine vitro vivo women